Simplify Logo

Full-Time

Senior Accountant

Confirmed live in the last 24 hours

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

201-500 employees

Develops treatments for neurodegenerative diseases

Hardware
Biotechnology

Senior, Expert

Remote in USA

Category
Budget Analysis
Financial Accounting
Management Accounting
Accounting
Requirements
  • 5+ years of relevant accounting experience
  • Bachelor’s degree in accounting
  • Intermediate proficiency with Microsoft Office Products (advanced Excel preferred)
Responsibilities
  • Prepare monthly account reconciliations, resolve discrepancies, and ensure accurate reporting
  • Participate in monthly PO accrual meetings with business owners and prepare required accrual journal entries
  • Reconcile cash transactions in a timely manner
  • Prepare intercompany markup calculations and journal entries
  • Calculate T&E accruals
  • Assist with the preparation of the actual vs. actual analysis
  • Manage month-end close tasks to ensure timely and accurate completion
  • Support internal SOX and external audit requirements
  • Assist in the interim and year-end audit process
  • Participate in process improvement activities, including enhancing current financial processes and suggesting areas for improvement
  • Support the senior management team with various analyses and ad hoc projects
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes.

Company Stage

IPO

Total Funding

$548.9M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

-3%

1 year growth

8%

2 year growth

61%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful acquisition of Phase 3-ready avexitide from Eiger could diversify Amylyx's pipeline and open new revenue streams.
  • Interim data from the Phase 2 HELIOS trial shows promising results for AMX0035 in treating Wolfram syndrome, indicating potential for broader applications.
  • The appointment of experienced professionals like Dr. Bernhardt Zeiher to the Board of Directors strengthens the company's leadership and strategic direction.

What critics are saying

  • The failure of the Phase III PHOENIX trial and subsequent market withdrawal of Relyvrio raises concerns about the efficacy of Amylyx's treatments.
  • A significant workforce reduction by 70% under a restructuring plan could impact company morale and operational efficiency.

What makes Amylyx Pharmaceuticals unique

  • Amylyx Pharmaceuticals focuses on neurodegenerative diseases like ALS and Alzheimer's, setting it apart from competitors with broader therapeutic areas.
  • The company's flagship product, AMX0035, has shown significant treatment benefits in rigorous clinical trials, including the CENTAUR ALS trial, which is a strong validation of its efficacy.
  • Amylyx's commitment to community engagement and awareness campaigns, such as ALS Awareness Month, enhances its brand and builds a supportive community around its cause.